Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 13/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16650965 | 0.90 | BRD4 (0.53) | BRD4ALPL | |
| SCHEMBL16650216 | 0.86 | BRD4 (0.50) | BRD4PTGS2EP300 | |
| SCHEMBL21191120 | 0.85 | PTGS2 (0.47) | BRD4SCN9APTGS2SLC22A12 | |
| SCHEMBL21191159 | 0.83 | TRPA1 (0.37) | CXCR2 | |
| SCHEMBL21190878 | 0.82 | BRD4 (0.48) | BRD4SCN9APTGS2EP300 | |
| SCHEMBL21190856 | 0.82 | BRD4 (0.45) | BRD4PTGS2ALPL | |
| SCHEMBL21190900 | 0.81 | BRD4 (0.41) | BRD4SCN9APTGS2EP300 | |
| SCHEMBL21190905 | 0.80 | BRD4 (0.48) | BRD4SCN9APTGS2SLC22A12 | |
| SCHEMBL16650187 | 0.80 | TRPA1 (0.40) | — | |
| SCHEMBL21190910 | 0.80 | BRD4 (0.50) | BRD4SCN9APTGS2ALPLSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200354371-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-11-12 | — | — | US | disclosed |
| WO-2019141131-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | 中国科学院上海药物研究所 | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354371-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | BRD4, BRD1, BRD3 | BRD4 1/4885SCN9A 1896/4885PTGS2 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.